Drug intelligence / Profile preview

Heparol 400

Development stage: Unknown
Lead developer: Ingram Biosciences
Modality: Small Molecules
Administration: Oral

Overview

Heparol 400 is a nutritional supplement developed and marketed by Ingram Biosciences. Formulated as soft gelatin capsules, it contains a combination of 400 mg of tocopherol (vitamin E) and 500 mg of omega-3 fatty acids. The product functions through the antioxidant properties of vitamin E and the anti-inflammatory and lipid-modifying effects of omega-3 fatty acids. It is primarily indicated for cardiovascular support and general nutritional supplementation, and is commonly utilized as an adjunctive therapy in hepatology for hepatic support. Heparol 400 is WHO-GMP certified and is commercially available in India through pharmaceutical distributors and online pharmacies.

Brand names: Heparol 400Heparol400Heparol-400
Other names: Tocopherol 400 & Omega 3 Fatty Acid 500 mgVitamin E + Omega-3 formulation

Beyond the preview

Go deeper on Heparol 400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heparol 400.

Explore the full profile